Pulmonx Corp financial performance 2026

After a 49 % drop in short interest in mid‑July, Pulmonx Corp saw hedge funds increase their stakes while its share price hovered near $1.25. The company’s Q2 2026 earnings were released on July 29, confirming earlier guidance. Worldwide revenue was $22.8 million, a 5 % year‑over‑year decline, with U.S. sales falling 4 % to $14.2 million and international revenue decreasing 6 % to $8.6 million, primarily because of no sales in China. Excluding China, overseas revenue rose 12 %. The quarter delivered a record gross margin of 78 % and trimmed the net loss by roughly one‑third (34 % versus the prior year), producing earnings per share of –$0.24, which beat consensus estimates. Shares remained flat around $1.25 and the CEO reiterated confidence in returning to revenue growth. The earnings release was noted alongside other market updates, such as Barclays raising its price target for Blue Owl Capital.